Inavolisib for HER2-positive breast cancer (INAVO122)

Inavolisib has strong Phase 3 validation in PIK3CA-mutant HR+/HER2- MBC (INAVO120 met PFS with HR~0.43). INAVO122 extends to HER2+ maintenance with Phesgo backbone. PI3K pathway activation is common in HER2+ disease, providing mechanistic rationale. Adding a targeted agent to maintenance typically shows PFS benefit. Risks: unselected PIK3CA population, tolerability of triplet, and HER2+ patients already have strong Phesgo backbone making incremental benefit harder.

Phase 3, placebo-controlled maintenance design and a clinically established PFS endpoint support interpretability. Adding PI3K-pathway blockade to HER2 therapy is mechanistically plausible, but no prior efficacy data or biomarker-enrichment details are provided, while toxicity, discontinuation, and investigator-assessment introduce risk.

Phase 3 placebo-controlled maintenance design in first-line HER2-positive advanced disease uses a clinically relevant PFS endpoint after induction, supporting a credible signal test. However, the provided record gives no prior efficacy, biomarker-enrichment, sample-size, or operational detail; incremental maintenance benefit is therefore uncertain despite an appropriate endpoint.

Phase 3 design and a clear investigator-assessed PFS endpoint support a meaningful chance of success. The established HER2-directed backbone and maintenance setting are favorable, but the novel combination, recruiting status, long time to completion, and absence of disclosed efficacy or operational results leave substantial uncertainty.

Phase 3 recruiting trial of inavolisib + Phesgo maintenance vs placebo + Phesgo in untreated HER2+ ABC; PFS investigator-assessed primary endpoint up to 40mo; rationale from PI3K inhibition in HER2+ but unselected population and maintenance setting may yield modest effect; strong sponsor execution lowers operational risk.

Inavolisib is a mutant-selective PI3Kα inhibitor that already demonstrated a massive PFS benefit (HR 0.43) in PIK3CA-mutated HR+/HER2- breast cancer (INAVO120). PIK3CA mutations are a known resistance mechanism to HER2-targeted therapy. Given the biomarker-selected population and strong biological rationale, adding inavolisib to Phesgo maintenance has a high probability of success.

Phase‑3 recruiting trial of inavolisib plus standard HER2 therapy versus placebo plus same backbone. No efficacy data yet, but combination is biologically plausible and sponsor is large. Early‑stage uncertainty keeps intrinsic odds near 50‑60% with low confidence.

INAVO122 evaluates inavolisib (PI3Kα inhibitor) + Phesgo maintenance in HER2+ ABC after induction. Key risk: no PIK3CA biomarker enrichment per brief summary, diluting effect since inavolisib's benefit is strongest in PIK3CA-mut tumors. Maintenance setting after induction is novel; PFS gain may be modest. Investigator-assessed PFS has some bias risk. Still recruiting with 451 days to primary completion adds operational risk. Sponsor (Roche) and Phesgo backbone are positives, but HER2+ PI3Ki combos have mixed history.